Becton Dickinson stock gains on dividend and margin outlook
Published on 09/10/2026 at 22:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Becton, Dickinson and Company stock (ISIN US0718131099) closed at USD 180.00 on the NYSE on September 9, 2026, up 1.1% from the prior close as investors positioned around a quarterly cash dividend of USD 1.05 per share. According to a corporate wrap published on September 10, 2026, this move kept the shares near their recent trading range despite a softer broader US equity market environment.Ad-hoc-news
Dividend and recent price performance
The latest trading data show that Becton Dickinson stock finished the September 9, 2026 session at USD 180.00 on the NYSE, compared with a previous closing price of USD 178.05, marking a gain of 1.1% in a single day.Ad-hoc-news Intraday trading kept the shares in a narrow band between about USD 178 and USD 180, indicating contained short-term volatility around the ex-dividend level.Ad-hoc-news
The September 9, 2026 session coincided with the ex-dividend date for Becton Dickinson's latest quarterly cash payout of USD 1.05 per share, with payment scheduled for September 30, 2026.GNG Research Dividend-focused investors often pay close attention to such dates, and the combination of a stable price band and a confirmed payout underpins the stock's income appeal.
Growth and margin guidance from conference remarks
On September 10, 2026, Becton Dickinson shared more detail on its operating trajectory during remarks at the 21st annual Wells Fargo healthcare conference, highlighting internal growth and margin plans for 2026.ChoiceStock According to this conference coverage, Becton Dickinson reported third-quarter internal growth of 4.4%, with around 90% of its portfolio delivering growth in the high single-digit range.ChoiceStock
The same conference remarks indicated that Becton Dickinson is targeting margin improvement of 300 to 400 basis points in 2026, a quantified step-up that would mark a notable expansion compared with the prior margin base.ChoiceStock For investors, this combination of mid-single-digit internal revenue growth in the third quarter and a planned 300 to 400 basis point margin uplift in 2026 is central to the investment case, because it ties operational efficiency to top-line expansion. However, the conference note also flagged that the company framed its 2026 revenue outlook in qualitative, optimistic terms without a specific numerical range, which limits visibility on how fast overall sales might grow.ChoiceStock
Analyst view and valuation signals
From an external valuation perspective, one discounted cash flow analysis published on September 10, 2026 assessed Becton Dickinson stock as modestly to significantly overvalued depending on the model used.GuruFocus According to this analysis, the earnings-based DCF model points to an intrinsic value of USD 156.87 per share, implying that with a current price snapshot of USD 179.80, Becton Dickinson trades about 14.6% above that estimate.GuruFocus A separate free cash flow-based DCF in the same report yields a significantly lower intrinsic value of USD 102.16, which would correspond to a much larger implied overvaluation and a negative margin of safety of 76.0% if taken at face value.GuruFocus
Analyst consensus data add another layer to the picture. Based on recent overview figures, Becton Dickinson carries an average rating of Hold, with eight analysts recommending Buy, eight rating the stock Hold and one assigning a Sell rating.MarketBeat The same MarketBeat data show a consensus price target of USD 187.67, which is around USD 7.67 above the September 9, 2026 closing price of USD 180.00 and therefore implies moderate expected upside from that level if the average target were reached.MarketBeat For investors, the contrast between the DCF-based intrinsic values and the consensus target offers a clear quantified view of valuation tension: while the market price is above at least one fundamental model estimate, sell-side analysts still collectively see room for some price appreciation.
Risks and upcoming information catalysts
The conference commentary on September 10, 2026 also pointed to several risk factors that could influence Becton Dickinson's share performance in the coming quarters. According to this note, there is potential for growth deceleration in the fourth quarter, weakness in the vaccine business and ongoing geopolitical cost pressures, all of which could weigh on margins even as the company aims for a 300 to 400 basis point improvement in 2026.ChoiceStock The same coverage notes that key information has been reserved for an analyst day planned for December 10, 2026, which is expected to serve as a major communication event for strategic and financial updates.ChoiceStock For shareholders, this date stands out as an important medium-term catalyst alongside regular quarterly reporting.
In the nearer term, income investors will focus on the confirmed dividend timetable. Becton Dickinson's most recent ex-dividend date was September 9, 2026, with the USD 1.05 per share cash dividend scheduled to be paid on September 30, 2026.GNG Research The steady pattern of quarterly dividends is a key part of the stock's appeal for long-term holders, particularly against the backdrop of mid-single-digit internal growth and a structured margin improvement plan.
Stock level and investor takeaways
As of the close on September 9, 2026, Becton Dickinson stock traded at USD 180.00 on the NYSE, positioning the shares modestly below the consensus analyst price target of USD 187.67 and modestly above at least one cited intrinsic value estimate of USD 156.87. The combination of a USD 1.05 quarterly dividend payable on September 30, 2026, third-quarter internal growth of 4.4% and planned margin expansion of 300 to 400 basis points in 2026 provides a number-rich backdrop for investors assessing the balance between income, growth and valuation risk.
Becton Dickinson stock at a glance
- Company: Becton, Dickinson and Company Inc.
- ISIN: US0718131099
- Ticker: BDX
- Trading venue: NYSE
- Price (as of September 9, 2026): 180.00 USD
- Market capitalization: 48,980,000,000 USD (as of September 10, 2026)
- Sector / Industry: Health Care / Medical Instruments and Supplies
- Index membership: S&P 500
- Next earnings date: December 10, 2026
